ASCO Survey on COVID-19 Oncology (ASCO) Registry

Richard L. Schilsky, MD, FACP, FSCT, FASCO
Executive Vice President and Chief Medical Officer

February 2, 2021

ASCO COVID-19 Research and Analysis Steering Group

Chair: Otis Brawley – Johns Hopkins University
Chair-Elect: Deb Schrag – Dana-Farber Cancer Institute
Charu Aggarwal – University of Pennsylvania
Nancy Baxter – Melbourne School of Population and Global Health
Elwyn Cabebe – Stanford Cancer Center South Bay
Ronald Chen – University of Kansas
Abdul-Rahman Jazieh – King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center
Jennifer King – GO2 Foundation for Lung Cancer

Dax Kurbegov – Sarah Cannon Research Institute
Randall Oyer – Penn Medicine Lancaster General Health - Ann B Barshinger Cancer Institute
Electra Paskett – Ohio State University
Lisa Richardson – Director, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention
Gabrielle Rocque – University of Alabama
Keith Sigel – Mt. Sinai, Infectious Disease
Alex Spira – VA Cancer Specialists
Robin Yabroff – American Cancer Society

© 2021 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
ASCO Registry Overview

- **Goal:** Help the cancer community learn more about the patterns of symptoms and severity of COVID-19 among patients with cancer as well as how COVID-19 is impacting the delivery of cancer care and patient outcomes

- **Objectives:**
  - Analyze distribution of symptoms and severity of COVID-19 among people with cancer
  - Examine impact of COVID-19 on cancer treatment and outcomes
  - Document adaptations of cancer care to the pandemic

ASCO Registry Activity

- **Launched April 2020**
- **As of February 1, 2021:**
  - 70 practices signed agreements and more joining weekly
  - Data entered on 1,771 patients with cancer and COVID-19 by 48 practices
- **Initial Presentation:** July 2020 AACR Meeting on COVID-19 and Cancer
  - Changes to oncology practice due to COVID-19
- **ClinicalTrials.gov Identifier:** NCT04659135
Target Patient Population

- Confirmed COVID-19 Diagnosis and
- In active anti-cancer treatment
  - Initiating treatment for new diagnosis
  - Clinically evident cancer receiving anti-cancer treatment
  - Disease-free, but receiving any type of adjuvant therapy within 1 year after surgical resection
  - Clinically evident cancer receiving supportive care only

Registry Eligibility and Data Elements

- Key Data Elements:
  - Risk factors and demographics
  - COVID-19 symptoms, treatments and long-term outcomes
  - Cancer status at baseline, changes to treatment plans, and cancer outcomes
  - Pandemic impacts on practice patterns, care implementation, and resources
The ASCO Registry is supported by Conquer Cancer’s COVID Impacts Cancer Fund.

© 2021 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Changes to Cancer Care Delivery due to COVID-19

Presented at July 2020 COVID-19 and Cancer Meeting

• All practices accepting new cancer patients (31 reporting)
  ▪ 71% of practices scheduling appointments without delay
• All practices using telemedicine for patients in routine follow-up
  ▪ 35% of practices for all patients and 52% for some patients
• 49% of practices adjusting treatments to either reduce 1) need for patients to come to clinic or 2) time in clinic
  ▪ 23% switched to oral treatments that can be sent to patients’ homes
  ▪ 26% shortened infusion time for IV treatment
• 77% experiencing shortages in personal protective equipment
  ▪ No practices reported shortages in anti-cancer drugs

Questions?

Please contact CENTRA@asco.org for additional information or questions.

www.asco.org/asco-coronavirus-information/coronavirus-registry

www.asco.org/asco-coronavirus-information/coronavirus-registry/
covid-19-registry-data-dashboard